The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Recent advances in targeted agents for the treatment of lung cancer
Federico Cappuzzo, MD, PhD, Istituto Nazionale Tumori, Rome, Italy, talks on the latest developments in targeted therapies for lung cancer. There have been recent advances in targeting KRAS G12C, a notoriously difficult to treat alteration, with the targeting agents sotorasib and adagrasib demonstrating promising activity. The number of targeted agents is expanding, including for specific rearrangements such as in the RET gene, increasing the likelihood of improving patient survival. This interview took place during the virtual European Lung Cancer Congress 2022.
